Early Access — free while we kick the tires
EdgarHawk

Boughton Soleil

Chief Legal Officer

Officer
2 filings analyzed · 1 company · Latest 2025-01-23

Companies

Company Buys Sells Direction
Hims & Hers Health, Inc. HIMS 0 7 Net selling

Activity

January 2025
medium
Sell
54,153 shares
$1,619,108
Significance 6/10

CLO Boughton Soleil sells 54,153 shares at avg $29.90; stock currently $30.89, up 9.7% past 30d but company was unprofitable FY

Boughton Soleil (Chief Legal Officer) executed 2 separate sales totaling 54,153 shares for $1,619,108.04 on 2025-01-21, reducing holdings by 24.6% to 165,650 shares. The sales occurred at an average blended price of $29.90, close to current levels ($30.89), and follow a pattern at HIMS where Soleil has executed 5 prior trades with mixed timing results—2 of 3 measurable sells were well-timed at the 90-day mark. However, the company's fundamental backdrop shows complexity: latest quarterly revenue of $401,556,000 with net income of $75,588,000 contrasts against a full-year net loss, and the stock has rebounded 42.2% over 90 days from depressed levels. This significant reduction in insider holdings warrants scrutiny of management's confidence in near-term prospects, particularly given the company's profitability transition headwinds despite strong quarterly results.

high
Sell
268,932 shares
$7,463,195
Significance 6/10

CLO Boughton Soleil sells 268,932 shares for $7,463,195.04 at blended $27.75; reduces stake 61.3%

Chief Legal Officer Boughton Soleil executed 2 separate sales totaling 268,932 shares for $7,463,195.04 on 2025-01-06, reducing his holdings from 438,735 to 169,803 shares (61.3% reduction). His prior trades at HIMS show a timing pattern: 3 of 4 prior sells had negative 90-day returns, indicating he historically sold before declines at this ticker. The company reported $401,556,000.00 in latest quarterly revenue with $75,588,000.00 net income, but was unprofitable over its most recent full fiscal year despite 65.5% annual revenue growth. The current price of $27.67 is 19.2% below the 52-week high and down 19.2% over 30 days, though up 47.7% over 90 days, placing the sale near recent resistance levels after a significant rally.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access